Covid, R&D, clinical trials: how Pfizer will invest in France

The harvest was good for the 2022 harvest at the Choose France summit, the second part of which took place in Versailles on July 11. In particular, in the health sector: in January, Pfizer announced its intention to invest 520 million euros over five years in France to strengthen its production and research capacity in several therapeutic areas (oncology, rare diseases, immunology, vaccines…) . “Pfizer (…) is pleased to invest in France, where they recognize the value of innovation and encourage the development of the healthcare industry,” said Albert Bourla, CEO of the France-based group. Hexagon more than 65 years ago and today has 1100 employees.

A country of administrative delays, regulatory burdens and a lack of funding regularly cited by researchers and industry players, France is nonetheless an “attractive” investment country, according to Henriette Rosenquist, president of Pfizer France, who points to Challenges tricolor projects of the pharmaceutical giant.

Challenges As part of your investment plan, French manufacturer Novasep has joined the global supply chain of the Covid-19 drug Paxlovid. Where is this partnership?

Henrietta Rosenquist – A significant part of our investment is indeed aimed at combating the Covid-19 pandemic. We have entrusted Novasep, a company with whom we already cooperated, with the production of the active pharmaceutical ingredient (API) of our protease inhibitor against Covid-19. Thus, this manufacturer has combined our global supply network for this drug, which is spread over three continents. It contributes 20% to the production of 120 million boxes planned for this treatment in 2022. After the stage of technical transfer and installation of equipment, the Novasep plant in Murens [Pyrénées-Atlantiques, NDLR]began production on June 3.